Teva Pharmaceutical Industries Limited (TLV:TEVA)
| Market Cap | 111.55B |
| Revenue (ttm) | 55.55B |
| Net Income (ttm) | 2.36B |
| Shares Out | n/a |
| EPS (ttm) | 2.04 |
| PE Ratio | 47.25 |
| Forward PE | 11.54 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,630,248 |
| Average Volume | 1,493,570 |
| Open | 9,800.00 |
| Previous Close | 9,726.00 |
| Day's Range | 9,665.00 - 9,809.00 |
| 52-Week Range | 4,865.00 - 9,849.00 |
| Beta | 0.67 |
| RSI | 76.60 |
| Earnings Date | Jan 28, 2026 |
About TLV:TEVA
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]
Financial Performance
In 2024, TLV:TEVA's revenue was $16.54 billion, an increase of 4.40% compared to the previous year's $15.85 billion. Losses were -$1.64 billion, 193.2% more than in 2023.
Financial numbers in USD Financial StatementsNews
Goldman Sachs Raises TEVA Price Target to $35, Maintains Buy Rating | TEVA Stock News
Goldman Sachs Raises TEVA Price Target to $35, Maintains Buy Rating | TEVA Stock News
Insider Selling: Amir Weiss Unloads $371K Of Teva Pharmaceutical Indus Stock
Disclosed on December 18, Amir Weiss , Chief Accounting Officer at Teva Pharmaceutical Indus (NYSE: TEVA), executed a substantial insider sell as per the latest SEC filing. What Happened: A Form 4 fi...
Alvotech, Teva Secures U.S. License Entry Date For Eylea Biosimilar AVT06
(RTTNews) - Alvotech (ALVO) and Teva Pharmaceutical Industries Ltd. (TEVA) have secured a U.S. license entry date for AVT06, the proposed biosimilar to Regeneron's Eylea, setting the stage for a poten...
Alvotech, Teva reach settlement with Regeneron over Eylea biosimilar AVT06 in U.S.
Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
REYKJAVIK, Iceland and TEL AVIV, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for...
My Top 10 Portfolio Holdings for 2026
It's been another banner year on Wall Street, with the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite, respectively, higher by 14%, 16%, and 20% year-to-date. Although I've been a net sel...
Insider Sell: Amir Weiss Sells 12,300 Shares of Teva Pharmaceutical Industries Ltd (TEVA)
Insider Sell: Amir Weiss Sells 12,300 Shares of Teva Pharmaceutical Industries Ltd (TEVA)
3 Things You Need to Know if You Buy Teva Pharmaceutical Stock Today
Teva Pharmaceutical is more complex than you may realize, even though that's part of the company's plan.
Sagimet rises as licensing deal with Teva unit targets Madrigal drug
TEVA's Subsidiary Grants License to Sagimet for Innovative Drug Development
TEVA's Subsidiary Grants License to Sagimet for Innovative Drug Development
JP Morgan Raises Price Target for TEVA to $35, Maintains Overweight Rating | TEVA Stock News
JP Morgan Raises Price Target for TEVA to $35, Maintains Overweight Rating | TEVA Stock News
Should You Forget Teva Pharmaceutical and Buy These Unstoppable Stocks Instead?
Teva Pharmaceutical is a leader in generic drugs, but these struggling makers of branded drugs may be a better choice.
Teva Pharmaceutical (TEVA) to Remove Over 200 Patents from FDA's Orange Book
Teva Pharmaceutical (TEVA) to Remove Over 200 Patents from FDA's Orange Book
Teva seeks removal of over 200 patents from FDA Orange Book after FTC challenge
Teva (TEVA) Requests FDA to Remove Over 200 Patent Listings
Teva (TEVA) Requests FDA to Remove Over 200 Patent Listings
TEVA Stock Rating Update: B of A Securities Raises Price Target to $32 | TEVA Stock News
TEVA Stock Rating Update: B of A Securities Raises Price Target to $32 | TEVA Stock News
TEVA Stock: Barclays Initiates Coverage with Overweight Rating | TEVA Stock News
TEVA Stock: Barclays Initiates Coverage with Overweight Rating | TEVA Stock News
Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play
Teva holds bullish momentum, trading above key SMAs, as branded drugs and biosimilars drive growth despite generics softness.
Glenview Doubles Down on Teva Stock With $72 Million Buy, According to Recent SEC Filing
Share count rose by 868,457; position value increased by $71.98 million Post-trade stake: 16,692,680 shares valued at $337.19 million Holding now comprises 7.51% of fund AUM, making it the fund's 4th-...
Teva Pharmaceuticals Submits NDA For Olanzapine LAI
(RTTNews) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced the submission of a New Drug Application to the FDA for olanzapine extended-release injectab...
Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
PARSIPPANY, N.J. and TEL AVIV, Israel, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the submis...
Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Dr. Reddy's
Sandoz, Teva and Dr. Reddy's emerge as standouts as generic drugmakers lean on biosimilars, complex generics and tighter cost controls.
Unpacking the Latest Options Trading Trends in Teva Pharmaceutical Indus
Whales with a lot of money to spend have taken a noticeably bullish stance on Teva Pharmaceutical Indus . Looking at options history for Teva Pharmaceutical Indus (NYSE: TEVA) we detected 9 trades. I...
Teva Pharmaceutical (TEVA) Receives a Boost in Price Target by Goldman Sachs | TEVA Stock News
Teva Pharmaceutical (TEVA) Receives a Boost in Price Target by Goldman Sachs | TEVA Stock News
3 Generic Drug Stocks to Watch Amid Changing U.S. Landscape
Generic drugmakers face U.S. pricing pressure, but TEVA, SDZNY and RDY gain momentum through complex generics and biosimilars.